Impact of Procalcitonin-Guided Testing on Antibiotic Stewardship: A Retrospective Quality Improvement Study
DOI:
https://doi.org/10.22317/imj.v9i2.1312Keywords:
Procalcitonin, Antimicrobial Stewardship, Quality Improvement, Biomarkers, Infection, Drug Resistance, MicrobialAbstract
Objectives: This quality improvement study aimed to evaluate the impact of implementing restrictions on procalcitonin (PCT) testing to enhance antibiotic stewardship in a hospital setting.
Methods: A retrospective, single-phase analysis was conducted over a five-month period at Eastbourne District General Hospital, involving 66 patients admitted to acute medical wards who underwent PCT testing. Data were extracted from electronic hospital records, including e-search, PACS, Evolve, and microbiology department databases. The study examined the correlation between PCT levels and other clinical and inflammatory markers, including C-reactive protein (CRP), white cell count (WCC), neutrophils, National Early Warning Score 2 (NEWS2), and temperature.
Results: Restricting PCT testing resulted in a 40% reduction in inappropriate test requests. The use of PCT-guided decision-making was associated with a shortened duration of antibiotic therapy for lower respiratory tract infections (3–5 days compared to the standard 7–10 days). Strong positive correlations were observed between PCT and CRP (r = 0.985), WCC (r = 0.993), neutrophils (r = 0.986), NEWS2 (r = 0.958), and temperature (r = 0.960), all statistically significant (p < 0.0001).
Conclusions: Selective use of PCT testing can optimize antibiotic prescribing practices and support effective antimicrobial stewardship. Long-term success relies on guideline adherence, clinician education, and seamless integration of PCT protocols into electronic health systems.
References
Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375(9713):463–74.
Branche A, Neeser O, Mueller B, Schuetz P. Procalcitonin to guide antibiotic decision-making. Curr Opin Infect Dis. 2019;32(2):130–5. doi:10.1097/QCO.0000000000000522.
Centres for Disease Control and Prevention (CDC). Core Elements of Hospital Antibiotic Stewardship Programs. Atlanta, GA: CDC; 2019.
De Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomized, controlled, open-label trial. Lancet Infect Dis. 2016;16(7):819–27.
Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. N Engl J Med. 2018;379(3):236–49. doi:10.1056/NEJMoa1802670.
Kamat IS, Ramachandran V, Eswaran H, Guffey D, Musher DM. Use of procalcitonin in patients with various degrees of illness: a review. Mayo Clin Proc. 2020;95(6):1205–17.
Kip MM, Kusters R, Steuten LM, et al. Cost-effectiveness of procalcitonin testing to guide antibiotic treatment duration in critically ill patients: results from a randomized controlled multicentre trial. Crit Care. 2018;22(1):293.
Lee H. Procalcitonin as a biomarker of infectious diseases. Korean J Intern Med. 2013;28(3):285–91. doi:10.3904/kjim.2013.28.3.285.
Meisner M. Update on procalcitonin measurements. Ann Lab Med. 2014;34(4):263–73. doi:10.3343/alm.2014.34.4.263.
NHS England. Summary of national guidance and evidence on the use of procalcitonin testing to support the management of COVID-19 and other infections. Published December 2020. Available from: https://www.england.nhs.uk/publication/procalcitonin-pct-testing/
National Institute for Health and Care Excellence (NICE). Procalcitonin testing for diagnosing and monitoring sepsis [Diagnostics Guidance DG18]. London: NICE; 2015. Available from: https://www.nice.org.uk/guidance/dg18
O’Neill J. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. Review on Antimicrobial Resistance. London: Wellcome Trust & HM Government; 2016. Available from: https://amr-review.org/Publications.html
Schuetz P, Briel M, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2017;(10):CD007498.
Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient-level meta-analysis. Lancet Infect Dis. 2018;18(1):95–107.
Vaughan A, Fraher M, Chidwick K, et al. Restricting procalcitonin testing to critical care and microbiology approval improves stewardship. JAC Antimicrob Resist. 2019;1(2):dlz030. doi:10.1093/jacamr/dlz030.
Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(5):426–35.
World Health Organization. Global Action Plan on Antimicrobial Resistance. Geneva: WHO; 2015.
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Iraq Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.